Suppliers / Macleods Pharmaceuticals

Macleods Pharmaceuticals

India 2 duplicate records merged Updated 9 July 2026

Macleods Pharmaceuticals is an API and finished-dose manufacturer based in India. It holds 129 active US drug master files and 104 valid CEPs. Its filings concentrate with SAHPRA (ZA), US FDA and DAV (Vietnam). Its GMP standing is certified by MHRA (UK), NCELS (KZ) and CDSCO (India), among 11 authorities. Its most recent recorded inspection, by US FDA, closed on 23 August 2024 as VAI. Customs aggregates show $37.4M of exports covering 1,024 molecules to 85 destinations in 2025.

129
active US DMFs
104
valid CEPs
12
registered plants 2 with an FDA FEI number
1,515
filings across 29 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
5 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 23 August 2024 VAI US FDA
  • 20 October 2023 VAI US FDA
  • 26 May 2023 VAI US FDA
  • 1 November 2021 OAI US FDA
  • 10 August 2018 NAI US FDA
  • 24 November 2017 OAI US FDA
  • 8 September 2017 NAI US FDA
  • 29 May 2017 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Kachigam, United Arab Emirates Not on file
Solan, United Arab Emirates Not on file
Himachal Pradesh, United Arab Emirates Not on file
BILLINGHAM, United Kingdom Not on file
DISTRICT DHAR, India Not on file
Mumbai, India Not on file

6 further sites are on record.

What they file, and where

Molecule Regulators Docs
Sitagliptin EDQM, SFDA (Saudi Arabia), US FDA 8
Valsartan EDQM, SFDA (Saudi Arabia), US FDA 7
Aripiprazole EDQM, SFDA (Saudi Arabia), US FDA 6
Celecoxib EDQM, SFDA (Saudi Arabia), US FDA 5
Entacapone EDQM, US FDA 5
Vardenafil EDQM, SFDA (Saudi Arabia), US FDA 5
Clopidogrel EDQM, SFDA (Saudi Arabia), US FDA 4
Duloxetine EDQM, US FDA 4
Irbesartan EDQM, SFDA (Saudi Arabia), US FDA 4
Levofloxacin EDQM, SFDA (Saudi Arabia), US FDA 4
Show all 30 molecules on file
Metformin EDQM, SFDA (Saudi Arabia), US FDA 4
Montelukast EDQM, SFDA (Saudi Arabia), US FDA 4
Nitrofurantoin EDQM, US FDA 4
Propylthiouracil EDQM, SFDA (Saudi Arabia), US FDA 4
Rosuvastatin EDQM, SFDA (Saudi Arabia), US FDA 4
Tadalafil EDQM, SFDA (Saudi Arabia), US FDA 4
Tamsulosin EDQM, US FDA 4
Atomoxetine EDQM, US FDA 3
Candesartan Cilexetil EDQM, US FDA 3
Carbimazole EDQM, SFDA (Saudi Arabia) 3
Hydralazine EDQM, US FDA 3
Hydrochlorothiazide EDQM, US FDA 3
Indomethacin EDQM, US FDA 3
Lacosamide EDQM, US FDA 3
Levothyroxine EDQM, US FDA 3
Memantine SFDA (Saudi Arabia), US FDA 3
Moxifloxacin EDQM, US FDA 3
Nebivolol EDQM, US FDA 3
Olanzapine EDQM, US FDA 3
Olmesartan Medoxomil EDQM, SFDA (Saudi Arabia) 3

Also appears on these molecule pages

Show 78 more molecule pages
Celecoxib API Cephalexin finished dose Chlorthalidone API Cilostazol finished dose Clobetasol finished dose Clopidogrel API Dapagliflozin API Desvenlafaxine API Diclofenac API Diltiazem finished dose Dolutegravir API Domperidone finished dose Doxycycline finished dose Duloxetine API Empagliflozin API Emtricitabine API Escitalopram API Esomeprazole API Ezetimibe API Febuxostat API Fenofibrate finished dose Formoterol finished dose Gliclazide finished dose Haloperidol finished dose Hydralazine API Hydrochlorothiazide API Ibandronic Acid API Indomethacin API Irbesartan API Isoniazid finished dose Lacosamide API Lamivudine finished dose Lansoprazole API Levocetirizine finished dose Levofloxacin API Linagliptin API Losartan API Memantine API Metformin API Metoprolol API Mirabegron API Montelukast API Moxifloxacin API Nebivolol API Nitrofurantoin API Nystatin finished dose Olanzapine API Olmesartan API Olmesartan Medoxomil API Oxcarbazepine finished dose Pantoprazole API Pioglitazone API Pramipexole API Pregabalin API Propranolol API Pyrazinamide API Quetiapine API Rifampicin finished dose Ritonavir finished dose Rosuvastatin API Salbutamol finished dose Saxagliptin finished dose Sildenafil API Sitagliptin API Solifenacin finished dose Tadalafil API Tamsulosin API Telmisartan API Tenofovir Disoproxil API Ticagrelor API Tinidazole finished dose Tramadol API Trimetazidine finished dose Ursodeoxycholic Acid API Valsartan API Venlafaxine API Vildagliptin finished dose Zolmitriptan API

Filings and GMP by regulator

Regulator Filings GMP certificates
SAHPRA (ZA) 389 None
US FDA 251 3
DAV (Vietnam) 142 None
TMDA (TZ) 99 1
EMA 70 5
NMRC (NA) 62 None
MHRA (UK) None 6
NCELS (KZ) None 6
CDSCO (India) None 6
NAFDAC (NG) None 2
UZPHARM (UZ) None 2
ANVISA (Brazil) None 2
MFDS (Korea) None 2
FDA (GH) None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $107.3M 107
2025 Not reported $37.4M 85
2024 Not reported $5.3M 26
2023 Not reported $4.6M 18

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Macleods Pharmaceuticals comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 30 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 23 August 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts